Cervista® HPV HR
Cervista HPV HR from Hologic, a 14-type High Risk Screening Test, represents the next generation in HPV DNA testing and provides your lab new levels of efficiency, clinical accuracy and responsiveness.
There’s nothing more important in clinical testing than accuracy. That’s why Cervista HPV HR delivers consistently reliable results that give confidence to laboratories as well as physicians and their patients.
Cervista HPV’s clinical trial results met all objectives and proved to be comparable to those from the landmark ALTS trial, underscoring the test’s accuracy. Specifically, Cervista HPV’s NPV and sensitivity for CIN2+ as well as CIN3+, an immediate precursor to cervical cancer, closely matched ALTS levels, providing confidence in test results.
The Cervista HPV HR test has consistently demonstrated superior assay reliability and robustness for high-risk screening assays, including:
Cervista HPV HR test results are consistently reliable. Other tests may have indeterminate rates of 4% or more and problematic “equivocal” zones that confound interpretation.
“Finally, the Invader method contains an internal control to determine the presence of sufficient DNA for reliable results and for the presence of potentially interfering substances. The hc2 method does not contain this control; therefore, laboratory professionals will never know if a negative hc2 result is due to the absence of HPV DNA or a simple lack of cellularity on the liquid cytology sample.” 6
Johnson et al., AJCP 2008
1100% CIN3 Detection in ASC-US: 95% CI (85.1% - 100%)
3Hybrid Capture® 2 High-Risk HPV DNA Test® Package Insert #L00665, Rev. 2, 2007.
4Cervista HPV HR Package Insert #15-3053, 2009.
5Castle, PE, Solomon, D., et al. Human Papillomavirus Genotype Specificity of Hybrid Capture 2. J Clin
6Johnson LR, Starkey CR, et al. A Comparison of Two Methods to Determine the Presence of High-Risk HPV
Cervical Infections. Am J Clin Pathol. 2008;130:401-408.
7International Agency for Research on Cancer
Many competitive tests require numerous process checks. Cervista HPV HR, however, features a full four-hour walk-away period. Enhanced productivity makes Cervista HPV HR the clear choice for labs to optimize efficiency.
Substantially reduces patient
1Cervista HPV multicenter clinical trial, 2006-2008. Clinical and analytical data on file, Hologic, Inc.
2Solomon et al, JNCI, 2001